Medical Device News Magazine

Brinter and LED Tailor Partner

To implement an automatic photon disinfection system in the 3D bioprinter chamber

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Bioprinting startup Brinter has today announced a partnership with LED Tailor to introduce a new disinfecting blue light feature embedded in its multi-material 3D bioprinting solution Brinter®. The system enables the safe production of e.g. tissue models and drugs, and minimizes the need for separate cleanrooms, making bioprinters more portable and safe.

Brinter is a modular bioprinter that is able to print multi-material and highly complex tissue structures in 3D, providing advanced features needed for bioprinting. The device can print both stiff and soft materials, including but not limited to liquids and hydrogels with living cells, bio-paste, metal with binder material, and thermoplastics, while being easy to set up in a lab in minutes.

Blue light is a part of the visible light spectrum, from 400 nm to approximately 500 nm wavelength. Disinfecting blue light, while being completely safe for human beings, kills all forms of bacteria, yeast, and mold. Opposite to UV-light (100–400nm), visible blue light does not deteriorate materials or cause other hazardous effects.

The discovery that all microbes contain blue light-sensitive compounds inside their cells as a part of their natural metabolism has been the key to creating this effective disinfection system.

When these light-sensitive compounds are exposed to specific wavelengths of disinfecting blue light with a certain light intensity, a destructive chemical reaction starts. The end products of this reaction are reactive oxygen radicals inside the microbial cell. Reactive oxygen species (ROS) are molecules containing a very reactive oxygen component, which has the ability to cause damage to any structure inside the microbial cell and destroy it from the inside.

“Our photon disinfection innovation is an automatic and sustainable solution to microbe problems. The system enables safe bioprinting, production of food and beverages, restrains epidemics, and answers the needs of cleanrooms. Our solutions improve safety and vitality of employees and reduce microbiological and chemical risks in healthcare and industrial sites,” says Harri Rautio, CEO at LED Tailor.

“The partnership with LED Tailor makes Brinter the first 3D bioprinter in the world using blue light disinfection technology that can be utilized both inside and outside of the device to clean the environment around the bioprinter,” says Tomi Kalpio, CEO at Brinter.

Customers of Brinter include bio and pharmaceutical companies like Nanoform, as well as research organizations like VTT, BEST group at the University of Glasgow, Johannes Gutenberg University of Mainz, the University of Oulu, University of Turku, Åbo Akademi, Tampere University, and the University of Helsinki.

To date, Brinter is currently active in over 10 countries, including the USA, Germany, India, and the UK. Last month, the company recently launched its new entry-level model, Brinter Core.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”